DSKYF
Daiichi Sankyo Company, Limited
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Sell
-28/100
Last price
17.69
▲ 0.06 (0.34%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
17.63
Day high
18.70
Day low
18.70
Volume
5
Market cap
$32.19B
P/E (TTM)
19.02
52W range
13.85 – 29.15
Trailing performance
Returnvs SPY
1W
-3.39%
-5.3%
1M
-3.49%
-4.6%
3M
+5.86%
+1.3%
6M
-2.70%
-20.9%
YTD
-17.72%
-32.0%
1Y
-32.43%
-48.8%
3Y
-37.42%
-119.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DSKYF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.17M
Total on file
Fundamentals
Market cap$32.19B
Enterprise value$-105.17B
Revenue (TTM)$2.22T
Gross profit$1.52T
EBITDA$311.07B
Net income$262.86B
EPS (TTM)$0.93
Free cash flow$-192.88B
Total cash$637.85B
Total debt$500.48B
Book value / share$5.93
Shares outstanding1.82B
Float1.82B
Short % of float—
Dividend yield3.58%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E19.02
Forward P/E18.62
PEG ratio1.83
Price / sales—
Price / book2.98
EV / revenue-0.05
EV / EBITDA-0.34
Gross margin68.47%
Operating margin14.81%
Profit margin10.93%
Return on equity14.81%
Return on assets3.32%
Debt / equity29.39
Current ratio2.92
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.12T | $1.89T | $1.60T | $1.28T | +12.6% |
| Operating revenue | $2.12T | $1.89T | $1.60T | $1.28T | +12.6% |
| Cost of revenue | $669.04B | $415.80B | $415.32B | $363.52B | +60.9% |
| Gross profit | $1.45T | $1.47T | $1.19T | $914.95B | -1.1% |
| Research & development | $466.00B | $435.96B | $365.17B | $341.57B | +6.9% |
| Selling, general & admin | $780.68B | $731.20B | $637.00B | $471.22B | +6.8% |
| Total operating expense | $1.22T | $1.14T | $974.78B | $794.37B | +7.6% |
| Operating income | $229.09B | $331.93B | $211.59B | $120.58B | -31.0% |
| Net interest income | $32.83B | $22.25B | $25.46B | $6.29B | +47.6% |
| Pre-tax income | $263.43B | $355.63B | $237.23B | $126.85B | -25.9% |
| Tax provision | $3.56B | $59.87B | $36.22B | $17.67B | -94.1% |
| Net income | $259.87B | $295.76B | $200.73B | $109.19B | -12.1% |
| Net income to common | $259.87B | $295.76B | $200.73B | $109.19B | -12.1% |
| Basic EPS | 140.44 | 155.96 | 104.69 | 56.95 | -10.0% |
| Diluted EPS | 140.37 | 155.87 | 104.62 | 56.91 | -9.9% |
| EBIT | $271.42B | $367.49B | $243.26B | $135.33B | -26.1% |
| EBITDA | $348.88B | $436.13B | $302.91B | $203.12B | -20.0% |
| Basic shares | 1.85B | 1.90B | 1.92B | 1.92B | -2.4% |
| Diluted shares | 1.85B | 1.90B | 1.92B | 1.92B | -2.4% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $449.81B | $639.84B | $647.18B | $441.92B | -29.7% |
| Cash & short-term investments | $554.54B | $720.73B | $1.22T | $825.13B | -23.1% |
| Inventory | $692.38B | $514.91B | $438.11B | $301.61B | +34.5% |
| Total current assets | $2.14T | $1.91T | $2.17T | $1.50T | +12.2% |
| Property, plant & equipment | $596.56B | $498.52B | $421.69B | $348.91B | +19.7% |
| Goodwill & intangibles | $338.42B | $344.27B | $276.80B | $257.94B | -1.7% |
| Total assets | $4.01T | $3.46T | $3.46T | $2.51T | +15.9% |
| Total current liabilities | $885.02B | $754.03B | $723.40B | $530.26B | +17.4% |
| Current debt | $404.00M | $399.00M | $399.00M | $41.40B | +1.3% |
| Long-term debt | $300.08B | $100.93B | $101.31B | $101.69B | +197.3% |
| Total debt | $300.48B | $101.33B | $101.71B | $143.09B | +196.5% |
| Total liabilities | $2.34T | $1.83T | $1.77T | $1.06T | +27.7% |
| Retained earnings | $1.55T | $1.46T | $1.39T | $1.23T | +6.4% |
| Shareholder equity | $1.66T | $1.62T | $1.69T | $1.45T | +2.5% |
| Working capital | $1.26T | $1.16T | $1.45T | $964.79B | +8.8% |
| Net tangible assets | $1.33T | $1.28T | $1.41T | $1.19T | +3.6% |
| Shares issued | 1.89B | 1.91B | 1.95B | 1.95B | -0.7% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $263.43B | $355.63B | $237.23B | $126.85B | -25.9% |
| Depreciation & amortisation | $77.46B | $68.65B | $59.65B | $67.79B | +12.8% |
| Change in working capital | -$55.78B | -$186.44B | $337.31B | -$7.38B | +70.1% |
| Operating cash flow | $77.66B | $53.84B | $599.26B | $114.51B | +44.2% |
| Capital expenditure | -$149.00B | -$187.87B | -$122.79B | -$67.37B | +20.7% |
| Investing cash flow | -$148.24B | $334.17B | -$282.64B | -$257.78B | -144.4% |
| Dividends paid | -$128.43B | -$114.32B | -$67.08B | -$54.62B | -12.3% |
| Financing cash flow | -$97.88B | -$377.77B | -$123.56B | -$89.59B | +74.1% |
| Free cash flow | -$71.35B | -$134.03B | $476.47B | $47.15B | +46.8% |
| End cash position | $488.98B | $639.84B | $647.18B | $441.92B | -23.6% |
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Basic EPS | 37.72 | — | 46.03 | — |
| Diluted EPS | 37.70 | — | — | — |
| Basic shares | 1.82B | 1.85B | 1.86B | -1.7% |
| Diluted shares | 1.82B | 1.85B | — | -1.6% |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $449.81B | $542.16B | $639.84B | -17.0% |
| Cash & short-term investments | $554.54B | $593.59B | $720.73B | -6.6% |
| Accounts receivable | $741.14B | $616.85B | $619.10B | +20.1% |
| Inventory | $692.38B | $608.55B | $514.91B | +13.8% |
| Total current assets | $2.14T | $1.88T | $1.91T | +14.2% |
| Property, plant & equipment | $596.56B | $551.30B | $498.52B | +8.2% |
| Goodwill & intangibles | $338.42B | $344.12B | $344.27B | -1.7% |
| Total assets | $4.01T | $3.57T | $3.46T | +12.2% |
| Total current liabilities | $885.02B | $856.06B | $754.03B | +3.4% |
| Current debt | $404.00M | $100.40B | $399.00M | -99.6% |
| Long-term debt | $300.08B | $100.74B | $100.93B | +197.9% |
| Total debt | $300.48B | $201.14B | $101.33B | +49.4% |
| Total liabilities | $2.34T | $1.92T | $1.83T | +22.2% |
| Retained earnings | $1.55T | $1.49T | $1.46T | +4.2% |
| Shareholder equity | $1.66T | $1.65T | $1.62T | +0.7% |
| Working capital | $1.26T | $1.02T | $1.16T | +23.2% |
| Net tangible assets | $1.33T | $1.31T | $1.28T | +1.3% |
| Shares issued | 1.89B | 1.89B | 1.91B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $569.65B | +13.8% |
| Next quarter | — | — | $591.22B | +5.9% |
| Current year | — | — | $2.36T | +30.5% |
| Next year | — | — | $2.41T | +2.0% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.17%
Held by institutions57.24%
Institutions holding447
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.22
-2.91% from price
SMA 20
18.25
-3.04% from price
SMA 50
17.68
+0.05% from price
SMA 100
17.03
+3.89% from price
SMA 200
18.03
-1.87% from price
EMA 12
18.05
-1.98% from price
EMA 26
18.04
-1.96% from price
EMA 50
17.78
-0.48% from price
RSI (14)
45.2
Neutral
MACD (12,26,9)
0.01
Hist -0.17
ATR (14)
0.31
1.74% of price
Realised vol 30D
51.4%
Annualised
Bollinger upper
19.46
20, 2σ
Bollinger lower
17.03
20, 2σ
50 / 200 cross
Death
17.68 vs 18.03
Trend bias
Below 200
-1.87%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.38
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
51.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-48.9%
Peak to trough
Max drawdown 5Y
-66.8%
Peak to trough
ATR 14
0.31
1.74% of price
Beta (reported)
—
5Y monthly, from filing
Dividends & splits
Forward rate$0.63 / yr
Forward yield3.58%
5-year avg yield0.97%
Payout ratio55.57%
Ex-dividend dateMar 30, 2027
Next pay dateDec 1, 2011
Last split3:1
Split dateSep 29, 2020
Headlines
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
Zacks · 2d ago
Will there be more to Daiichi’s story than DXd ADCs?
Pharma Voice · 2d ago
Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
Simply Wall St. · 5d ago
Sector Update: Healthcare Stocks Steady Late Afternoon
MT Newswires · 5d ago
AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
GuruFocus.com · 5d ago
Sector Update: Healthcare Stocks Softer in Afternoon Trading
MT Newswires · 5d ago
Sector Update: Healthcare
MT Newswires · 5d ago
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
Pharmaceutical Technology · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.